Mission Bio Inc. has created the first assay capable of determining measurable residual disease in cancer down to the level of individual cells.
The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School.
